Skip to main content

Lung Cancer

Conference Highlights ASCO, Lung Cancer, Oncology

Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC

Phoebe Starr

Lung Cancer, Oncology

EGFR Most Common Mutation in Women with Lung Cancer and No Smoking History

Walter Alexander

Walter Alexander

Lung Cancer, Infectious Diseases, Oncology

Patients with Lung Cancer Distressed About Impact of COVID-19 on Access to Care

Walter Alexander

Walter Alexander

FDA Approvals, Lung Cancer, Oncology

Tagrisso Approved as Adjuvant Therapy for NSCLC with EGFR Mutations

Lung Cancer, Oncology

Adjuvant Osimertinib a Practice-Changing Treatment in Early-Stage NSCLC with EGFR Mutation

Wayne Kuznar

Lung Cancer, Oncology

Capmatinib Shows Activity in MET-Amplified Non–Small-Cell Lung Cancer

Wayne Kuznar

Lung Cancer, Oncology

Durvalumab plus Chemotherapy New Standard of Care for Extensive-Stage Small-Cell Lung Cancer

Phoebe Starr

FDA Approvals, Lung Cancer, Oncology

FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation

FDA Approvals, Lung Cancer, Oncology

Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression

FDA Approvals, Lung Cancer, Oncology

Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma

Page 1 of 5
Results 1 - 10 of 44